Little common ground in stent controversy

Bad news first: Heart attack victims are more likely to die if they're fitted with a drug-coated stent than if they're given a bare one, according to an analysis of 2,300 patients in 14 countries, known as the Grace Registry.

But opposite-and-somewhat-equal good news, also presented at the European Society of Cardiology congress: Swedish researchers following drug-coated stent patients found no increased risk of death. And Boston Scientific, which makes the Taxus drug-eluting stent, also announced results of its own study--no increased risk of blood clots in patients four to five years on. (We'll take this latter study with a grain of salt, however.)

For its part, Johnson & Johnson, which markets the Cypher drug stent, deemed the Grace Registry findings "inconsistent" with other studies (those with results it likes better, of course).

- here's the report on the heart-attack study
- see the report on the Swedish study here
- check out release from Boston Scientific

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.